Search
risankizumab (Skyrizi)
Indications:
- moderate to severe plaque psoriasis*
- psoriatic arthritis*
- moderate to severe Crohn's disease
- may be effective for induction & maintenance of ulcerative colitis [3]
* >50% achieve clear skin in 1 year [2]
Dosage:
- 90-180 mg SQ every 4-12 weeks
Mechanism of action:
- inhibits IL-23
Interactions
drug adverse effects of immunosuppressive agents
monitor with immunosuppressive agents
General
pharmaceutical monoclonal antibody
immunosuppressive agent
References
- Papp KA, M.D., Blauvelt A, Bukhalo A et al
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque
Psoriasis.
N Engl J Med 2017; 376:1551-1560. April 20, 2017
PMID: 28423301
http://www.nejm.org/doi/full/10.1056/NEJMoa1607017
- Bassett M
Risankizumab Resolves Psoriasis in Half of Patients.
Superior to ustekinumab for many endpoints in two RCTs.
MedPage Today. February 19, 2018
https://www.medpagetoday.com/meetingcoverage/aad/71238?
- Gordon K et al
Efficacy and safety of risankizumab: Results from two double-
blind, placebo- and ustekinumab-controlled, phase 3 trials
in moderate-to-severe plaque psoriasis.
American Academy of Dermatology (AAD) 2018
- Louis E, Schreiber S, Panaccione R et al
Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials.
JAMA. 2024 Jul 22:e2412414.
PMID: 39037800
https://jamanetwork.com/journals/jama/fullarticle/2821291